Defence Therapeutics Inc. (OTCMKTS:DTCFF) Sees Significant Drop in Short Interest

Defence Therapeutics Inc. (OTCMKTS:DTCFF) saw a large drop in short interest in February. As of February 15th, there was short interest totalling 2,900 shares, a drop of 29.3% from the January 31st total of 4,100 shares. Based on an average trading volume of 4,300 shares, the days-to-cover ratio is currently 0.7 days.

Defence Therapeutics Price Performance

Shares of OTCMKTS DTCFF remained flat at $0.79 during trading on Tuesday. Defence Therapeutics has a 12 month low of $0.27 and a 12 month high of $1.32. The business’s 50-day moving average is $0.63 and its 200-day moving average is $0.50.

About Defence Therapeutics

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.